Background:

Brentuximab vedotin (BV) is an antibody-drug conjugate targeting CD30 which has been approved for the treatment of adult patients with CD30-positive lymphomas, specifically relapsed or refractory systemic anaplastic large cell lymphoma (sALCL) and classical Hodgkin lymphoma (cHL). This study presents a retrospective analysis of BV's efficacy and safety in CD30-positive lymphoma patients at our institution.

Methods:

This study included CD30-positive lymphoma patients treated with BV from July 2020 to April 2024. The primary endpoint was the overall response rate (ORR). The secondary endpoints were complete response (CR) rate, progression-free survival (PFS), overall survival (OS) and adverse events (AEs). Efficacy was assessed based on the 2014 Lugano Conference, and treatment-related AEs were evaluated according to CTCAE5.0.

Results:

A total of 66 patients were analyzed. The median age at diagnosis was 40 years (range: 15-79 years), with 43 (65.1%) being male. The patient cohort included 39 (59.1%) with cHL, 26 (39.4%) with peripheral T-cell lymphoma (PTCL), and 1 (1.5%) with primary mediastinal large B-cell lymphoma (PMBL). Two (3.0%) had previously undergone stem cell transplantation. The median number of prior chemotherapy lines was 0.5 (range: 0-7). B symptoms were present in 24 (36.4%). 5 (7.6%) had an ECOG score ≥ 2 and 43 (65.2%) exhibited extranodal disease. 22 patients (33.3%) had spleen involvement and 38 (57.6%) had elevated erythrocyte sedimentation rate at diagnosis. Disease progression was noted in 26 (39.4%) prior to BV treatment. BV was combined with chemotherapy in 65 patients (98.5%), while 1 patient (1.5%) received BV monotherapy. The median follow-up time was 13.75 months. There were 6 deaths due to tumor progression, 1 due to low platelet count, and 1 patient due to pulmonary embolism. The median PFS and OS were not reached. The ORR was 89.4% (59/66) and the CR rate was 66.7% (44/66). Common AEs included leukopenia (30.3%) and anemia (10.6%), with other AEs being abnormal liver function, nausea, fatigue, gastrointestinal reactions, numbness of the limbs, rash, decreased appetite, etc. Grade 3-4 AEs comprised of leukopenia (15.1%).

Conclusions:

BV shows significant efficacy in treating CD30-positive lymphoma with acceptable safety, supporting its role as a valuable therapeutic option for these patients.

Disclosures

No relevant conflicts of interest to declare.

This content is only available as a PDF.
2024
Sign in via your Institution